Clinical Trial Update: Optiquel® as Corticosteroid-sparing Therapy for Chronic Noninfectious Uveitis [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial update for Optiquel® as a corticosteroid-sparing therapy in chronic noninfectious uveitis; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uveitis

Drugs mentioned

• Optiquel®

Snippet

Sponsor: National Eye Institute (NEI) | Conditions: Uveitis | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2014-12-05